Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023

SELL
$30.21 - $48.1 $1.68 Million - $2.67 Million
-55,557 Reduced 29.19%
134,783 $4.48 Million
Q4 2022

Feb 13, 2023

BUY
$22.28 - $38.71 $959,555 - $1.67 Million
43,068 Added 29.24%
190,340 $5.84 Million
Q2 2022

Aug 11, 2022

BUY
$23.14 - $49.68 $996,570 - $2.14 Million
43,067 Added 41.33%
147,272 $5.11 Million
Q1 2022

May 13, 2022

SELL
$27.77 - $64.4 $1.01 Million - $2.34 Million
-36,386 Reduced 25.88%
104,205 $4.58 Million
Q4 2021

Feb 11, 2022

BUY
$54.9 - $105.21 $5.62 Million - $10.8 Million
102,421 Added 268.33%
140,591 $8.84 Million
Q3 2021

Nov 09, 2021

SELL
$105.0 - $178.37 $681,450 - $1.16 Million
-6,490 Reduced 14.53%
38,170 $4.02 Million
Q1 2021

May 13, 2021

SELL
$126.27 - $191.71 $1.14 Million - $1.72 Million
-8,996 Reduced 16.77%
44,660 $5.96 Million
Q4 2020

Feb 12, 2021

SELL
$81.94 - $135.34 $1.2 Million - $1.99 Million
-14,681 Reduced 21.48%
53,656 $7.26 Million
Q1 2020

May 15, 2020

SELL
$39.1 - $62.9 $1.59 Million - $2.57 Million
-40,792 Reduced 37.38%
68,337 $3.52 Million
Q4 2019

Feb 13, 2020

SELL
$29.79 - $43.06 $357,271 - $516,418
-11,993 Reduced 9.9%
109,129 $4.54 Million
Q2 2019

Aug 14, 2019

SELL
$25.73 - $35.79 $302,507 - $420,783
-11,757 Reduced 8.85%
121,122 $4.22 Million
Q4 2018

Feb 14, 2019

BUY
$14.95 - $24.72 $727,003 - $1.2 Million
48,629 Added 57.72%
132,879 $3.09 Million
Q3 2018

Nov 15, 2018

BUY
$17.8 - $25.35 $1.14 Million - $1.63 Million
64,250 Added 321.25%
84,250 $1.64 Million
Q4 2017

Feb 15, 2018

BUY
$21.23 - $34.09 $424,600 - $681,800
20,000
20,000 $424,000

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.55B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Platinum Investment Management LTD Portfolio

Follow Platinum Investment Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Platinum Investment Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Platinum Investment Management LTD with notifications on news.